Amgen Inc. $AMGN Stock Sold by Teachers Retirement System of The State of Kentucky

Amgen logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Kentucky’s Teachers Retirement System cut its Amgen stake by 62.4% in the third quarter, selling 70,060 shares; it retained 42,218 shares valued at about $17.8 million.
  • Amgen reported quarterly earnings of $6.45 per share, beating the $5.79 analyst consensus, while revenue rose 8.5% year over year to $10.37 billion.
  • The company declared a quarterly dividend of $2.52 per share, equivalent to $10.08 annually and a 2.2% yield at the article’s cited share price.
  • MarketBeat previews the top five stocks to own by December 1st.

Teachers Retirement System of The State of Kentucky reduced its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 62.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,218 shares of the medical research company's stock after selling 70,060 shares during the period. Teachers Retirement System of The State of Kentucky's holdings in Amgen were worth $17,795,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in AMGN. Willow Creek Capital Management Inc. increased its holdings in shares of Amgen by 1.0% in the 3rd quarter. Willow Creek Capital Management Inc. now owns 4,114 shares of the medical research company's stock worth $1,734,000 after buying an additional 39 shares during the last quarter. Paralel Advisors LLC lifted its holdings in shares of Amgen by 1.1% in the 3rd quarter. Paralel Advisors LLC now owns 6,640 shares of the medical research company's stock valued at $2,799,000 after acquiring an additional 75 shares during the last quarter. Proactive Wealth Strategies LLC lifted its holdings in shares of Amgen by 0.8% in the 3rd quarter. Proactive Wealth Strategies LLC now owns 7,249 shares of the medical research company's stock valued at $3,055,000 after acquiring an additional 56 shares during the last quarter. BCS Private Wealth Management Inc. lifted its holdings in shares of Amgen by 19.4% in the 3rd quarter. BCS Private Wealth Management Inc. now owns 5,731 shares of the medical research company's stock valued at $2,416,000 after acquiring an additional 931 shares during the last quarter. Finally, Western Wealth Management LLC grew its position in Amgen by 2.0% in the third quarter. Western Wealth Management LLC now owns 10,497 shares of the medical research company's stock worth $4,424,000 after acquiring an additional 209 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Price Performance

Shares of AMGN stock opened at $457.93 on Wednesday. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. The company has a market capitalization of $247.70 billion, a P/E ratio of 26.56, a P/E/G ratio of 3.22 and a beta of 0.43. The company's 50-day simple moving average is $427.10 and its two-hundred day simple moving average is $382.34. Amgen Inc. has a one year low of $312.39 and a one year high of $483.99.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, topping analysts' consensus estimates of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The business had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. During the same period last year, the company posted $5.64 earnings per share. The company's quarterly revenue was up 8.5% compared to the same quarter last year. As a group, equities analysts anticipate that Amgen Inc. will post 23.37 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 annualized dividend and a yield of 2.2%. Amgen's dividend payout ratio is 58.47%.

Key Headlines Impacting Amgen

These are some of the AMGN headlines that stood out recently:

  • Positive Sentiment: Amgen has raised its 2026 outlook twice, with newer products helping offset pressure on Prolia and XGEVA. A broader biotech-industry report also cites strong 2026 results and raised outlooks among leading companies, including Amgen. Amgen outlook and product pressures Biotechnology market outlook
  • Positive Sentiment: Amgen’s obesity-treatment candidate is described as a potential rival in a market led by Novo Nordisk, offering a possible future growth opportunity. Novo Nordisk versus Amgen
  • Neutral Sentiment: Amgen published detailed Phase 3 results for dazodalibep in Sjögren’s disease, adding clinical information for investors; the article excerpt does not specify the results’ implications. Dazodalibep Phase 3 data

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Citigroup boosted their price objective on Amgen from $405.00 to $465.00 and gave the stock a "neutral" rating in a research note on Wednesday, November 4th. Piper Sandler raised their price objective on Amgen from $427.00 to $457.00 and gave the company an "overweight" rating in a research note on Thursday, August 20th. Truist Financial raised their price objective on Amgen from $380.00 to $398.00 and gave the company a "hold" rating in a research note on Wednesday, November 4th. BMO Capital Markets dropped their target price on Amgen from $450.00 to $415.00 and set a "market perform" rating for the company in a report on Monday, October 12th. Finally, Mizuho boosted their target price on Amgen from $303.00 to $352.00 and gave the company a "neutral" rating in a research report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $425.69.

Check Out Our Latest Stock Analysis on Amgen

Amgen Profile

(Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company's medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Featured Stories

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Amgen Right Now?

Before you consider Amgen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.

While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines